Genetic Ancestry Testing Useful for Health Planning

Seamless pattern of hand drawn faces of various ethnicities

Researchers from Mount Sinai have shown that genetic ancestry can be used to better understand and predict who is more susceptible to certain disorders—including cancers, asthma, diabetes, and cardiovascular disease. They point out that this information could be used to develop early interventions.

Their study was reported in the journal Cell.

“This is the first time researchers have shown how genetic ancestry data could be used to enhance our understanding of disease risk and management at a health system level,” says senior author Eimear Kenny, Ph.D., Professor of Medicine, and Genetics and Genomic Sciences, at the Icahn School of Medicine at Mount Sinai. “By linking this data directly to health outcomes, we believe we’re contributing to an ongoing conversation to move beyond the current role of race and ethnicity in medicine.”

It is estimated that almost 30 million people have taken genetic ancestry tests, which focus on genealogy. Whether these tests are useful for health decisions and planning has been debated.

The research team drew from Mount Sinai’s BioMe BioBank program, a repository of genomic information for diverse populations, for its study. Using machine learning methodology, they identified 17 distinct ethnic communities from among the 30,000 participants in the BioMe BioBank. This data was then linked to thousands of health outcomes in Mount Sinai’s electronic health records. Among the findings was that 25 percent of BioMe participants had genetic links to populations–such as Ashkenazi Jewish and Puerto Rican–that predisposed them to certain genetic diseases.

“The traditional use of demographic data by health systems fails to capture the rich ethnic heritage of patients, and thus all the genetic and environmental factors that can affect rates of disease even within the same population,” says Kenny, Founding Director of the Institute for Genomic Health at Mount Sinai.

“Our study used genomic data embedded in health system records to show how patients with origins from different countries in the Americas can have different rates of disease. For example, people of Puerto Rican and Mexican descent are broadly classified as Hispanic or Latinx, yet the former population has one of the highest rates of asthma in the world, while the latter population has one of the lowest.”

The Mount Sinai study cited the APOL1 gene, which can confer a significantly greater risk of kidney and cardiovascular disease. The risk variants of APOL1 are most frequently seen in populations across the Americas that share African genetic ancestry. However, there are many populations around the world of African descent that might not self-identify as African, and thus be unaware that they might harbor those risk variants. Furthermore, that knowledge gap may result in these populations being underrepresented in APOL1 research.

“Our study underscores that there are limits to the narrow demographic labels used in medicine and research today–and society in general, for that matter–to attempt to characterize disease and its risk factors,” says Kenny. “The types of information that can be derived from using biological markers of ancestry, however, convey a much richer and more sophisticated layer of understanding of disease risk and burden, one that could have enormous implications for health care systems globally.”

This site uses Akismet to reduce spam. Learn how your comment data is processed.